Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety cohort study of dupilumab in moderate-to-severe asthma after completion of TRAVERSE-LTS12551
MOH_2019-02-21_004835Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in asthma, sponsored by Sanofi. Primary endpoint: Long-term safety of dupilumab. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2019-02-21_004835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-21_004835.